Size | Price | Stock | Qty |
---|---|---|---|
5mg |
|
||
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
500mg |
|
||
Other Sizes |
|
Purity: ≥98%
Targets |
wild type reverse transcriptase(IC50= 4.5 nM);K103N reverse transcriptase(IC50= 5.5 nM);Y181C reverse transcriptase(IC50= 6.1 nM)
|
---|---|
ln Vitro |
Doravirine is a highly specific nonnucleoside reverse transcriptase inhibitor with very little off-target activity, according to studies on selectivity and cytotoxicity. Doravirine exhibits remarkable efficacy in inhibiting the replication of WT virus, with a 95% effective concentration (EC95) of 20 nM, and mutant viruses K103N, Y181C, and K103N/Y181C, with EC9595 of 43, 27, and 55 nM, respectively, when 50% normal human serum (NHS) is present. Comparable antiviral effects of doravirine have been observed against 93 viruses, representing 10 distinct HIV-1 subtype viruses[1].
|
ln Vivo |
When 50 mg of doravirine is administered along with a high-fat meal, there is no change in Cmax but there are modest increases in AUC time zero to infinity and C24 h[2].
|
References |
|
Molecular Formula |
C17H11CLF3N5O3
|
|
---|---|---|
Molecular Weight |
425.752
|
|
Exact Mass |
425.05
|
|
Elemental Analysis |
C, 47.96; H, 2.60; Cl, 8.33; F, 13.39; N, 16.45; O, 11.27
|
|
CAS # |
1338225-97-0
|
|
Related CAS # |
|
|
Appearance |
Solid powder
|
|
SMILES |
N#CC1=CC(OC2=C(C(F)(F)F)C=CN(CC(N3C)=NNC3=O)C2=O)=CC(Cl)=C1
|
|
InChi Key |
ZIAOVIPSKUPPQW-UHFFFAOYSA-N
|
|
InChi Code |
InChI=1S/C17H11ClF3N5O3/c1-25-13(23-24-16(25)28)8-26-3-2-12(17(19,20)21)14(15(26)27)29-11-5-9(7-22)4-10(18)6-11/h2-6H,8H2,1H3,(H,24,28)
|
|
Chemical Name |
3-Chloro-5-((1-((4-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)methyl)-2-oxo-4-(trifluoromethyl)-1,2-dihydropyridin-3-yl)oxy)benzonitrile
|
|
Synonyms |
|
|
HS Tariff Code |
2934.99.9001
|
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO : 85 ~100 mg/mL (199.64~234.88 mM)
|
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: 2.5 mg/mL (5.87 mM) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (5.87 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. View More
Solubility in Formulation 3: 10% DMSO+40% PEG300+5% Tween-80+45% Saline: 2.5 mg/mL (5.87 mM) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.3488 mL | 11.7440 mL | 23.4880 mL | |
5 mM | 0.4698 mL | 2.3488 mL | 4.6976 mL | |
10 mM | 0.2349 mL | 1.1744 mL | 2.3488 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Susceptibility of mutant viruses containing NNRTI-associated mutants to NNRTIs. (A) MK-1439; (B) EFV; (C) RPV; (D) ETR. th> |
---|
Susceptibility of a panel of 96 clinically relevant NNRTI-associated mutant viruses to NNRTIs. (A) MK-1439; (B) EFV; (C) RPV; (D) ETR. Mean three-dimensional plot of MK-1439 and other antiviral agents in the two-drug combination study.Antimicrob Agents Chemother.2014;58(3):1652-63. |
Susceptibility of EFV, ETR, and RPV Resistant Viruses to MK-1439. (A) MK-1439- versus EFV-resistant viruses; (B) MK-1439- versus RPV-resistant viruses; (C) MK-1439- versus ETR-resistant viruses. Susceptibility of RPV-associated mutant viruses to NNRTIs.Antimicrob Agents Chemother.2014;58(3):1652-63. td> |